Prothena Corporation PLC (PRTA) and Its Competitors Financial Review

Prothena Corporation PLC (NASDAQ: PRTA) is one of 296 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Prothena Corporation PLC to related companies based on the strength of its analyst recommendations, risk, earnings, valuation, profitability, institutional ownership and dividends.

Profitability

This table compares Prothena Corporation PLC and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Prothena Corporation PLC -527.56% -33.20% -27.66%
Prothena Corporation PLC Competitors -5,492.74% -451.92% -42.73%

Valuation and Earnings

This table compares Prothena Corporation PLC and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Prothena Corporation PLC $27.53 million -$135.60 million -14.09
Prothena Corporation PLC Competitors $263.26 million $68.25 million -6.44

Prothena Corporation PLC’s rivals have higher revenue and earnings than Prothena Corporation PLC. Prothena Corporation PLC is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Prothena Corporation PLC has a beta of 2.59, suggesting that its share price is 159% more volatile than the S&P 500. Comparatively, Prothena Corporation PLC’s rivals have a beta of 6.66, suggesting that their average share price is 566% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Prothena Corporation PLC and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prothena Corporation PLC 0 0 12 0 3.00
Prothena Corporation PLC Competitors 766 3049 11236 227 2.72

Prothena Corporation PLC presently has a consensus price target of $79.73, suggesting a potential upside of 37.34%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.80%. Given Prothena Corporation PLC’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Prothena Corporation PLC is more favorable than its rivals.

Institutional and Insider Ownership

50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 3.1% of Prothena Corporation PLC shares are owned by company insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

About Prothena Corporation PLC

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company’s pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.

What are top analysts saying about Prothena Corporation PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Prothena Corporation PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit